{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-011475","form_type":"8-K","ticker":"ACRS","cik":"0001557746","company_name":"Aclaris Therapeutics, Inc.","filed_at":"2022-08-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.147356+00:00","generated_at":"2026-06-24T06:27:55.046609+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aclaris Therapeutics appoints Douglas Manion as President and COO effective August 1, 2022","bullets":["Douglas Manion appointed President and COO effective August 1, 2022; Neal Walker remains CEO.","Receives annual base salary of $490,000, target annual bonus of 40% of salary.","Granted stock options for 217,800 shares at $13.62 exercise price and RSU award for 62,300 shares.","Equity awards vest over four years; severance includes 12 months base salary plus COBRA if terminated without cause.","Previously EVP R&D at Arena Pharmaceuticals and held leadership roles at BMS."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-011475","json":"https://secwatch.observer/filing/0001558370-22-011475.json","markdown":"https://secwatch.observer/filing/0001558370-22-011475.md","text":"https://secwatch.observer/filing/0001558370-22-011475.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1557746/000155837022011475/0001558370-22-011475-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1557746/000155837022011475/acrs-20220801x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T06:27:55.046609+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"358ab23abc","claim":"Douglas Manion was appointed as President and Chief Operating Officer at Aclaris Therapeutics, Inc..","evidence_excerpt":"appointed Douglas Manion, M.D., FRCP (C), as the Company’s President and Chief Operating Officer effective August 1, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1557746/000155837022011475/0001558370-22-011475-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Operating Officer"}],"fact_type":"executive_change"},{"claim_id":"46da2707cc","claim":"Neal Walker changed role as President at Aclaris Therapeutics, Inc..","evidence_excerpt":"Neal Walker will no longer serve as the Company’s President, but will continue to serve as the Company’s Chief Executive Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1557746/000155837022011475/0001558370-22-011475-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"no longer serve as"},{"label":"Role","value":"President"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}